CHMP backs use of Celgene's Abraxane in pancreatic cancer
This article was originally published in Scrip
Executive Summary
Hot on the heels of FDA approval of Abraxane (paclitaxel protein-bound particles for injectable suspension) in combination with gemcitabine as a first–line treatment for advanced pancreatic cancer (scripintelligence.com, 6 September 2013) experts at the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) are recommending the Celgene drug be approved for the same indication in Europe.